The retrospective analysis of the frequency of EGFR mutations and the efficacy of gefitinib in NSCLC patients with brain metastasis.

e18065 Background: Some reports have showed that brain metastasis (BM) in the advanced NSCLC patients has higher EGFR mutations. Gefitinib (TKI) has shown the effectiveness in patients with advanced NSCLC. This retrospective study is to analyze the EGFR mutation rate and the efficacy of TKI on the NSCLC patients with brain metastasis in our group. METHODS… (More)